Prilenia has announced preliminary results of its PROOF-HD trial on pridopidine on Huntington’s disease. While the study missed both its primary endpoint (an improvement in the Unified Huntington Disease Rating Scale-Total Functional Capacity) and a key secondary endpoint by (Composite Unified Huntington’s Disease Rating Scale (cUHDRS)), the company was encouraged by positive signals in a range of other trial read-outs. These preliminary results have been announced only eight days after the study end, so EHDN looks forward to more detailed analysis of these important results.